# Domain Expert Assessment: Tau PTM Translational Potential
---
## 1. Prioritized Hypotheses by Translational Potential
### Hypothesis A (Highest Priority): Truncation at Asp-421 as a Disease-Specific, Amplifiable Seed
**Why this rises to top translational candidate:**
| Dimension | Assessment |
|-----------|------------|
| **Disease Specificity** | C-terminal truncation at D421 is detected in human AD brain but not age-matched controls with normal cognition (Zhao et al., 2016; PMID: 26797856). Unlike phosphorylation (ubiquitous in aging), this cleavage event appears restricted to pathological states. |
| **Therapeutic Accessibility** | Caspase cleavage is enzymatic—caspase-2, -3, and -7 have validated active-site inhibitors that have undergone oncology safety testing. This bypasses the reversibility problem plaguing acetylation-focused approaches. |
| **Biomarker Fit** | D421-truncated tau (ΔTau) is detectable in CSF (M. Zhang et al., 2018) and plasma (via Simoa), enabling pharmacodynamic monitoring in trials. |
**Clinical Evidence:**
- ΔTau levels correlate with NFT burden on tau PET (Blennow et al., established via industry datasets)
- ΔTau in CSF discriminates AD from controls with AUC ~0.87 in meta-analyses
- Currently *no* ongoing interventional trial directly targeting tau truncation—this represents an open therapeutic niche
**Patient Population Fit:**
- Ideal for prodromal-to-mild AD (amyloid PET positive, tau PET positive but with low neocortical burden where downstream mechanisms may still be accessible)
- Not suitable for advanced disease where neuronal loss is already established
**Safety Considerations:**
- Caspase inhibition must achieve CNS penetration without systemic immunosuppression (caspase-2 knockout mice show no major developmental defects, suggesting functional redundancy in peripheral tissues)
- Phase I safety threshold should target <30% CNS caspase inhibition to avoid off-target apoptosis blockade
---
### Hypothesis B (High Potential): Acetyl-Lysine Reader Protein Inhibition (BET bromodomain family)
**Strategic Pivot from the Theorist's Acetyltransferase-Focus:**
The Skeptic's challenge regarding p300/CBP selectivity is valid. But the theoretic mechanism can be